<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">
hero-press-releases-1

Newsroom

Press Releases

Our latest announcements

Biodesix to Present Data at IASLC 2022 World Conference

Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors

Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022

Biodesix announced today that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4

Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis

Adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment

Biodesix Obtains Medicare Coverage for Nodify CDT® Lung Nodule Test

The Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, provides coverage for the Nodify CDT® lung nodule test.

Biodesix Announces Research Agreement with Top US Cancer Center

Aim is to develop and commercialize new pipeline oncology biomarker assay in collaboration with Memorial Sloan Kettering Cancer Center and Bio-Rad, Inc.

Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference

Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9 in Chicago

Biodesix Announces First Quarter 2022 Results and Highlights

First Quarter 2022 Financial Results

Biodesix Announces Publication Further Validating the use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients with Cancer

Biodesix today announced that new data were published in the peer-reviewed journal, Diagnostics (Basel), in an article titled, “Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants.”

Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights

Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods

Biodesix Announces impactful Clinical Data on the Primary Immune Response (PIR) test at the IASLC 2022 Therapies of Lung Cancer Meeting

Biodesix announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting.

First 1 2 3 4 5 6 7 8 9 Last